{
    "clinical_study": {
        "@rank": "19991", 
        "arm_group": [
            {
                "arm_group_label": "Omega 3 fatty acid supplementation", 
                "arm_group_type": "Experimental", 
                "description": "Omacor 2 grams daily"
            }, 
            {
                "arm_group_label": "Olive Oil", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Olive Oil capsule 2 grams daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The mechanisms through which omega-3 fatty acids reduce adverse cardiac events remain\n      uncertain. The aim of the study was to investigate the effect of omega-3 fatty acid\n      supplementation on endothelial vasomotor function, endogenous fibrinolysis, and platelet and\n      monocyte activation in patients with coronary heart disease."
        }, 
        "brief_title": "Effect of Omega 3 Fatty Acids on Vascular Function", 
        "completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "condition": "Previous Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Twenty patients with a previous myocardial infarction were recruited into a randomised,\n      double-blind, placebo-controlled, crossover trial of omega-3 fatty acid supplementation\n      (2g/day for 6-weeks). Peripheral blood was taken for analysis of platelet and monocyte\n      activation, and forearm blood flow was assessed in a subset of 12 patients during\n      intrabrachial infusions of acetylcholine, substance P and sodium nitroprusside. Stimulated\n      plasma tissue plasminogen activator (t-PA) concentrations were measured during substance P\n      infusion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022 Myocardial infarction at least 3 months previously.\n\n        Exclusion Criteria:\n\n          -  Dietary fish allergy or intolerance\n\n          -  Women of child bearing potential\n\n          -  Malignant arrhythmias\n\n          -  Renal or hepatic failure\n\n          -  Severe or significant co-morbidity\n\n          -  Previous history of blood dyscrasia\n\n          -  Unable to tolerate the supine position\n\n          -  Lack of informed consent\n\n          -  Blood donation within last 3 months"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888211", 
            "org_study_id": "LREC/2003/8/13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega 3 fatty acid supplementation", 
                "description": "2 grams Omacor daily", 
                "intervention_name": "Omega 3 fatty acid supplementation", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Olive Oil", 
                "description": "2 grams olive oil daily", 
                "intervention_name": "Olive Oil", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edinburgh", 
                    "country": "United Kingdom", 
                    "state": "Scotland", 
                    "zip": "EH16 4SB"
                }, 
                "name": "Centre for Cardiovascular Sciences, University of Edinburgh"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Omega 3 Fatty Acid Supplementation on Endothelial Function, Endogenous Fibrinolysis and Platelet Activation in Patients With a Previous Myocardial Infarction", 
        "overall_official": [
            {
                "affiliation": "University of Edinburgh", 
                "last_name": "David E Newby", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Edinburgh", 
                "last_name": "Jehangir N Din", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Endogenous fibrinolysis was measured by drawing blood during intrabrachial substance P infusion and then plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit; Technoclone, Vienna, Austria) concentrations were determined by enzyme-linked immunosorbent assays. Estimated net release of plasma t-PA was the product of the infused forearm plasma flow (based on the mean hematocrit and the infused forearm blood flow) and the concentration difference between the infused and noninfused arms.", 
            "measure": "Endogenous fibrinolysis (net release of plasma t-PA,IU mL-1)", 
            "safety_issue": "No", 
            "time_frame": "Measured at 6 weeks after omega 3 fatty acids or placebo"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888211"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Forearm blood flow was measured during intrabrachial infusions of acetylcholine, substance P and sodium nitroprusside by venous occlusion plethysmography with mercury-in-silicone elastomer strain gauges.", 
                "measure": "Endothelial vasomotor function (forearm blood flow, mL l00 mL-1 min-1)", 
                "safety_issue": "No", 
                "time_frame": "Measured at 6 weeks after omega 3 fatty acids or placebo"
            }, 
            {
                "description": "Whole blood was immunolabelled with appropriate monoclonal antibodies for subsequent flow cytometric analysis of platelet-monocyte aggregation. Platelet-monocyte aggregates were defined as the percentage of monocytes positive for CD42a.", 
                "measure": "Circulating platelet-monocyte aggregates (%).", 
                "safety_issue": "No", 
                "time_frame": "Measured at 6 weeks after omega 3 fatty acids or placebo"
            }
        ], 
        "source": "University of Edinburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Edinburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2004", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}